Brain Tumor Clinical Trials

Full title:

ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Study goal:

The first part of this study is complete. The second part (phase 2) aims to study how well selinexor works with radiation to treat DIPG and HGG.

Diagnosis:

Diffuse intrinsic pontine glioma, also known as diffuse midline glioma, H3 K27M-mutant; High-grade glioma (HGG) with H3K27M; HGG with wild-type H3K27M, and no mutation in BRAF V600E or IDH

Age:

12 months to 21 years

Full title:

Phase 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age with NTRK1/2/3 or ROS1-fused CNS Tumors (GLOBOTRK)

Study goal:

To find out whether entrectinib is effective in treating brain tumors with NTRK or ROS1 fusions

Diagnosis:

High-grade glioma and other CNS tumors

Age:

Birth–3 years old

Full title:

Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

Study goal:

The main purpose of this study is to find out what happens, good and bad, to memory and learning when the hippocampus is avoided during proton therapy radiation.

Diagnosis:

Low-grade glioma

Age:

At least 6 years old and younger than 22

Full title:

A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients with Hypothalamic Obesity, with an Open-Label Extension 

Study goal:

To find out if taking the medicine LB54640 is safe and effective to control the weight and hunger of people with hypothalamic obesity.

Diagnosis:

Brain tumors

Age:

12 and up

Full title:

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors 

Study goal:

The main goal of this study is to test the safety of selpercatinib in children and adolescents with solid tumors or brain and spinal cord tumors. Researchers also want to learn how the drug affects cancer in children and the best, most effective dose.

Diagnosis:

Solid tumors, brain tumors

Age:

6 months to 21 years old

Full title:

Locoregional Delivery of B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cells for Pediatric Patients with Primary CNS Tumors

Study goal:

The purpose of this study is to find: 1) the largest dose of Loc3CAR T cells that is safe to give patients with B7-H3–positive brain tumors; 2) the side effects of Loc3CAR T cells; 3) the effect Loc3CAR T cells have on brain tumors. This trial will help scientists better understand how the immune system fights this kind of tumor. What we learn from this study could help us create better treatments.

Diagnosis:

Brain tumors, DIPG, DMG

Age:

Up to 21 years old

Full title:

Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

Study goal:

 To see if savolitinib is safe and tolerable in children with brain tumors

Diagnosis:

Medulloblastoma, high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG)

Age:

Between 5 years old and 21 years old

Full title:

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

Study goal:

The main goal of this study is to learn if proton therapy will treat patients with craniopharyngioma brain tumors effectively and reduce side effects compared to traditional forms of radiation therapy.

Diagnosis:

Craniopharyngioma

Age:

21 years old or younger

Full title:

SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma

Study goal:

The main goal of this study is to test the experimental drug mirdametinib in hopes of finding a treatment that may be effective against low-grade glioma brain tumors in children, adolescents and young adults.

Diagnosis:

Low-grade glioma

Age:

At least 2 years old and younger than 25 years old.

Full title:

SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

Study goal:

To establish a lifetime group of childhood cancer survivors treated at St. Jude Children’s Research Hospital and to evaluate health outcomes in aging survivors of pediatric cancer

Age:

Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude

Full title:

SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

Study goal:

To collect information about the effects of childhood cancer and its treatment on the patients who are treated or followed after treatment for childhood cancer at St. Jude Children’s Research Hospital

Full title:

SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma

Study goal:

This study uses a risk-directed approach to find out which types of treatment will work best and have the fewest side effects for infants and children with medulloblastoma.

Diagnosis:

Medulloblastoma

Age:

Birth to 5 years old

Full title:

Components of Social Functioning in Survivors of Pediatric Brain Tumors

Study goal:

Examine the impact of social-cognitive and neurocognitive abilities on social functioning in survivors of pediatric brain tumors

Diagnosis:

Brain tumor

Full title:

Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression

Study goal:

To identify recurrent verbal and nonverbal communication techniques employed by pediatric oncologists in the delivery of difficult prognostic information to parents through content analysis of audio recorded conversations between pediatric oncologists and parents of children with high-risk cancer at times of disease re-evaluation

Diagnosis:

Non-therapeutic

Age:

Patients: Age 30 or younger
Parents: Age 18 or older